HONG KONG – It's been more than a year since Chinese authorities leveled allegations against Glaxosmithkline plc (GSK) for corrupt activities amounting to almost $500 million in bribes, setting off an industrywide crackdown that has garnered the attention of not only the Chinese, but also the U.S. and UK anti-corruption authorities.